Alpha-1 Antitrypsin Deficiency

Schiff's Diseases of the Liver

Volumn , Issue , 2011, Pages 845-867

  Perlmutter, David H ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Aggregation prone proteins; Autophagy; Chronic obstructive pulmonary disease; Cirrhosis; Emphysema; Hepatitis; Hepatocellular carcinoma; Proteasomal degradation pathway; Protein homeostasis; Proteostasis

Indexed keywords

EID: 84880623078     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119950509.ch31     Document Type: Chapter

References (164)

1. Sveger T. Liver disease in α1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316-21.
2. Wilson-Cox D. Alpha-1-antitrypsin deficiency. In: Scriver CB, Beaudet AL, Sly WS, et al., eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989: 2409-37.
3. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360:2749-57.
4. Sharp HL, Bridges RA, Krivit W. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969;73:934-9.
5. Hope PL, Hall MA, Millward-Sadler GH, et al. Alpha-1-antitrypsin deficiency presenting as a bleeding diathesis in the newborn. Arch Dis Child 1982;57:68-70.
6. Ghishan FR, Gray GF, Greene HL. α1-Antitrypsin deficiency presenting with ascites and cirrhosis in the neonatal period. Gastroenterology 1983;85:435-8.
7. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in α1-antitrypsin deficiency. N Engl J Med 1986;314:736-9.
8. Sveger T. α1-Antitrypsin deficiency in early childhood. Pediatrics 1978;62:22-35.
9. Piitulainen E, Carlson J, Ohlsson K, Sveger T. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver and protease/protease inhibitor studies. Chest 2005;128:2076-81.
10. Nebbia G, Hadchouel M, Odievre M, et al. Early assessment of evolution of liver disease associated with α1-antitrypsin deficiency in childhood. J Pediatr 1983;102:661-5.
11. Ibarguen E, Gross CR, Savik SK, et al. Liver disease in α1-antitrypsin deficiency: prognostic indicators. J Pediatr 1990;117:864-70.
12. Volpert D, Molleston JP, Perlmutter DH. α1-Antitrypsin deficiencyassociated liver disease progresses slowly in some children. J Pediatr Gastroenterol Nutr 2000;31:258-63.
13. Hodges JR, Millward-Sadler GH, Barbatis C, et al. α1-Anti-trypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med 1981;304:357-60.
14. Graziadel IW, Joseph JJ, Wiesner RH, et al. Increased risk of chronic liver failure in adults with heterozygous α1-antitrypsin deficiency. Hepatology 1998;28:1058-63.
15. Propst T, Propst A, Dietze O, et al. High prevalence of viral infections in adults with homozygous and heterozygous α1-antitrypsin deficiency and chronic liver disease. Ann Intern Med 1992;117:641-5.
16. Reid CL, Wiener GJ, Cox DW, et al. Diffuse hepatocellular dysplasia and carcinoma associated with the Mmalton variant of α1-antitrypsin. Gastroenterology 1987;93:181-7.
17. Curiel DT, Holmes MD, Okayama H, et al. Molecular basis of the liver and lung disease associated with α1-antitrypsin deficiency allele Mmalton. J Biol Chem1989;264:13938-45.
18. Crowley JJ, Sharp HL, Freier E, et al. Fatal liver disease associated with α1-antitrypsin deficiency PIM1/PIMduarte. Gastroenterology 1987;93:242-4.
19. Clark P, Chong AYH. Rare alpha-1-antitrypsin allele PIW and a history of infant liver disease. Am J Med Genet 1993;45:674-6.
20. Kelly CP, Tyrrell DNM, McDonald GSA, et al. Heterozygous FZ α1-antitrypsin deficiency associated with severe emphysema and hepatic disease: case report and family study. Thorax 1989;44:758-9.
21. Brantly ML, Paul LD, Miller BH, et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988;128:327-36.
22. Janus ED, Philips NT, Carrell RW. Smoking, lung function and α1-antitrypsin deficiency. Lancet 1985;1:152-4.
23. Hird MF, Greenough A, Mieli-Vergani G, et al. Hyperinflation in children with liver disease due to α1-antitrypsin deficiency. Pediatr Pulmonol 1991;11:212-16.
24. Wiebicke W, Niggermann B, Fischer A. Pulmonary function in children with homozygous alpha-1-protease inhibitor deficiency. Eur J Pediatr 1996;155:603-7.
25. Bernspang B, Wollmer P, Sveger T, Piitulainen E. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals. Respir Med 2009;103:861-5.
26. Schonfeld JV, Brewer N, Zotz R, et al. Liver function in patients with pulmonary emphysema due to severe alpha-1-antitrypsin deficiency (PIZZ). Digestion 1996;57:165-9.
27. Rabin M, Watson M, Kidd V, et al. Regional location of α1-antichymotrypsin and α1-antitrypsin genes on human chromosome Somat Cell Mol Genet 1986;12:209-14.
28. Long GL, Chandra T, Woo SLC, et al. Complete nucleotide sequence of the cDNA for human α1-antitrypsin and the gene for the S variant. Biochemistry 1984;23:4828-37.
29. Perlino E, Cortese R, Ciliberto G. The human α1-antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes. EMBO J 1987;6:2767-71.
30. Hafeez W, Ciliberto G, Perlmutter DH. Constitutive and modulated expression of the human α1-antitrypsin gene: different transcriptional initiation sites used in three different cell types. J Clin Invest 1992;89:1214-22.
31. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem2001;276:33293-6.
32. Elliott PR, Abrahams JP, Lomas DA. Wild type α1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol 1998;275:419-25.
33. Pierce JA, Eradio BG. Improved identification of antitrypsin phenotypes through isoelectric focusing with dithioerythritol. J Lab Clin Med 1979;94:826-31.
34. Crystal RG. Alpha-1-antitrypsin deficiency, emphysema and liver disease: genetic basis and strategies for therapy. J Clin Invest 1990;95:1343-52.
35. BrantlyM, Lee JH, Hildeshiem J, et al. α1-Antitrypsin genemutation hot spot associated with the formation of a retained and degraded null variant. Am J Respir Cell Mol Biol 1997;16:225-31.
36. Sifers RN, Brashears-Macatee S, Kidd VJ, et al. A frameshift mutation results in a truncated α1-antitrypsin that is retained within the rough endoplasmic reticulum. J Biol Chem1988;263:7330-5.
37. Frazier GC, Siewersen MA, Hofker MH, et al. A null deficiency allele of α1-antitrypsin, QO Ludwigshafen, with altered tertiary structure. J Clin Invest 1990;86:1878-84.
38. Lin L, Schmidt B, Teckman J, et al. A naturally occurring nonpolymerogenic mutant of α1-antitrypsin characterized by prolonged retention in the endoplasmic reticulum. J Biol Chem 2001;276:33893-8.
39. Owen MC, Brennan SO, Lewis JH, et al. Mutation of antitrypsin to antithrombin: α1-antitrypsin Pittsburgh (358 Met-Arg) - a fatal bleeding disorder. N Engl J Med 1983;309:694-8.
40. Curiel DT, Vogelmeier C, Hubbard RC, et al. Molecular basis of α1-antitrypsin deficiency and emphysema associated with α1-antitrypsin M mineral springs allele. Mol Cell Biol 1990;10:47-56.
41. Teckman JH, Perlmutter DH. The endoplasmic reticulum degradation pathway for mutant secretory proteins α1-antitrypsin Z and S is distinct from that for an unassembled membrane protein. J Biol Chem 1996;271:J13215-20.
42. Seyama K, Nukiwa T, Takabe K, et al. Siiyma serine 53 (TCC) of phenylalanine 53 (TCC): a new α1-antitrypsin deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem1991;266:12627-32.
43. Senior RM, Tegner H, Kuhn C, et al. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 1977;116:469-75.
44. Gadek JE, Fells GA, Zimmerman RL, et al. Antielastase of the human alveolar structures: implication for the protease-antiprotease theory of emphysema. J Clin Invest 1981;68:889-98.
45. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983;52:655-709.
46. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition of deformation. Nature 2000;407:923-6.
47. Carrell RW, Lomas DA. Conformational disease. Lancet 1997;350:134-6.
48. Carp H, Janoff A. Possible mechanisms of emphysema in smokers: in vitro suppression of serum elastase inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. Am Rev Respir Dis 1978;118:617-21.
49. Ossanna PJ, Test ST, Matheson NR, et al. Oxidative regulation and neutrophil elastase-alpha-1-proteinase inhibitor interactions. J Clin Invest 1986;72:1939-51.
50. Hubbard RC, Ogushi F, Fells GA, et al. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of α1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest 1987;80:1289-95.
51. Mast AE, Enghild J, Nagase H, et al. Kinetics and physiologic relevance of the inactivation of α1-proteinase inhibitor, α1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/ type IV collagenase), and -3 (stromelysin). J Biol Chem 1991;266: 15810-16.
52. Liu Z, Zhou X, Shapiro SD, et al. The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000;102:647-55.
53. Liu Z, Shapiro SD, Zhou X, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000;105:113-23.
54. Duranton J, Boudier C, Belorgey D, et al. DNA strongly impairs the inhibition of cathepsin G by α1-antichymotrypsin and α1-proteinase inhibitor. J Biol Chem2000;275(6):3787-92.
55. Bathurst IC, Travis J, George PM, et al. Structural and functional characterization of the abnormal Z α1-antitrypsin isolated from human liver. FEBS Lett 1984;177:179-83.
56. Ogushi F, Fells GA, Hubbard RC, et al. Z-type α1-antitrypsin is less competent thanM1-type α1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;89:1366-74.
57. Libert C, Van Molle W, Brouckaert P, et al. α1-Antitrypsin inhibits the lethal response to TNF in mice. J Immunol 1996;157:5126-9.
58. Camussi G, Tetta C, Bussolino F, et al. Synthesis and release of platelet-activating factor is inhibited by plasma α1-proteinase inhibitor or α1-antichymotrypsin and is stimulated by proteinases. J ExpMed 1988;168:1293-306.
59. Ikari Y, Mulvihill E, Schwartz SM. α1-Proteinase inhibitor, α1-antichymotrypsin, and β2-macroglobulin are the antiapoptotic factors of vascular smoothmuscle cells. J Biol Chem2001;276:11798-803.
60. Banda MJ, Rice AG, Griffin GL, et al. The inhibitory complex of human α1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant. J ExpMed 1988;167:1608-15.
61. Perlmutter DH, Travis J, Punsal PI. Elastase regulates the synthesis of its inhibitors, α1-proteinase inhibitor, and exaggerates the defect in homozygous PIZZ α1-proteinase inhibitor deficiency. J Clin Invest 1988;81:1774-80.
62. Perlmutter DH, Glover GI, Rivetna M, et al. Identification of a serpin-enzyme complex (SEC) receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990;87:3753-7.
63. Joslin G, Fallon RJ, Bullock J, et al. The SEC receptor recognizes a pentapeptide neo-domain of α1-antitrypsin-protease complexes. J Biol Chem1991;266:11281-8.
64. Joslin G, Griffin GLI, August AM, et al. The serpin-enzyme complex (SEC) receptor mediate the neutrophil chemotactic effect of α1-antitrypsin-elastase complexes and amyloid-_-peptide. J Clin Invest 1992;90:1150-4.
65. Parmar JS, Mahadeva R, Reed BJ, et al. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002;26:723-30.
66. Shapiro L, Pott GB, Ralston AH. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 2001;15:115-22.
67. Munch J, Standker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007;129:263-75.
68. Lewis EC, Mizrahi M, Toledano M, et al. α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA 2008;105:16236-41.
69. Pott GB, Chan ED, Dinarello CA, Shapiro L. α1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009;85:886-95.
70. Hood JM, Koep LJ, Peters RL, et al. Liver transplantation for advanced liver disease with α1-antitrypsin deficiency. N Engl J Med 1980;302:272-6.
71. Lodish HF, Kong N. Glucose removal from N-linked oligosaccharides is required for efficient maturation of certain secretory glycoproteins from the rough endoplasmic reticulum to the Golgi complex. J Cell Biol 1987;104:221-30.
72. Liu MC, Yu S, Sy J, et al. Tyrosine sulfation of proteins from human hepatoma cell line HepG2. Proc Natl Acad Sci USA 1985;82:7160-4.
73. DeSimone V, Cortese R. Transcription factors and liver-specific genes. J Biol Biophys Acta 1992;1132:119-26.
74. Hu C, Perlmutter DH. Regulation of α1-antitrypsin gene expression in human intestinal epithelial cell line Caco2 by HNF1- and HNF4. Am J Physiol 1999;276:G1181-94.
75. Triposi M, Abbott C, Vivian M, et al. Disruption of the LF-A1 and LF-B1, binding sites in the human alpha-1-antitrypsin gene, has a differential effect during development in transgenic mice. EMBO J 1991;10:3177-82.
76. Dickson I, Alper CA. Changes in serum proteinase inhibitor levels following bone surgery. Clin Chim Acta 1974;54:381-5.
77. Perlmutter DH, May LT, Sehgal PB. Interferon β2/interleukin-6 modulates synthesis of α1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest 1989;264:9485-90.
78. Laurell CB, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy and estrogens. J Clin Endocrinol Metab 1979;49:719-25.
79. Perlmutter DH, Cole FS, Kilbridge P, et al. Expression of the α1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci USA 1985;82:795-9.
80. Barbey-Morel C, Pierce JA, Campbell EJ, et al. Lipopolysaccharide modulates the expression of α1-proteinase inhibitor and other serine proteinase inhibitors in human monocytes and macrophages. J Exp Med 1987;166:1041-54.
81. Joslin G, Wittwer A, Adams S, et al. Cross-competition for binding of α1-antitrypsin (_-1-AT)-elastase complexes to the serpin-enzyme complex receptor by other serpin-enzyme complexes and by proteolytically modified-1-AT. J Biol Chem1993;268: 1886-93.
82. Joslin G, Krause JE, Hershey AD, et al. Amyloid-peptide, substance P and bombesin bind to the serpin-enzyme complex receptor. J Biol Chem1991;266:21897-902.
83. Kelsey GD, Povey S, Bygrave AE, et al. Species- and tissue-specific expression of human alpha-1-antitrypsin in transgenic mice. Genes Dev 1987;1:161-70.
84. Molmenti EP, Perlmutter DH, Rubin DC. Cell-specific expression of α1-antitrypsin in human intestinal epithelium. J Clin Invest 1993;92:2022-34.
85. Venembre P, Boutten A, Seta N, et al. Secretion of α1-antitrypsin by alveolar epithelial cells. FEBS Lett 1994;346:171-4.
86. Cichy J, Potempa J, Travis J. Biosynthesis of α1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem 1997;272(13):8250-5.
87. Hu C, Perlmutter DH. Cell-specific involvement of HNF1- in alpha-1-antitrypsin gene expression in human respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002;282:L757-65.
88. Kounnas MZ, Church FC, Argraves WS, et al. Cellular internalization and degradation of antithrombin-III-thrombin, heparin cofactor II-thrombin, and α1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem 1996;271:6523-9.
89. Perlmutter DH, Joslin G, Nelson P, et al. Endocytosis and degradation of α1-antitrypsin-proteinase complexes is mediated by the SEC receptor. J Biol Chem1990;265:16713-16.
90. Mast AE, Enghild JJ, Pizzo SV, et al. Analysis of plasma elimination kinetics and conformation stabilities of native, proteinasecomplexed and reactive site cleaved serpins: comparison of α1-proteinase inhibitor, α1-antichymotrypsin, antithrombin III, β2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991;30:1723-30.
91. Thomas DW, Sinatra FR, Merritt RJ. Random fecal alpha-1-antitrypsin concentration in children with gastrointestinal disease. Gastroenterology 1981;80:776-82.
92. Kidd VJ, Walker RB, Itakura K, et al. α1-Antitrypsin deficiency detection by direct analysis of the mutation of the gene. Nature 1983;304:230-4.
93. Jeppsson JO. Amino acid substitution Glu-Lys in α1-antitrypsin PIZ. FEBS Lett 1976;65:195-7.
94. Perlmutter DH, Kay RM, Cole FS, et al. The cellular defect in α1-proteinase inhibitor deficiency is expressed in human monocytes and xenopus oocytes injected with human liver mRNA. Proc Natl Acad Sci USA 1985;82:6918-21.
95. Foreman RC, Judah JD, Colman A. Xenopus oocytes can synthesize but do not secrete the Z variant of human α1-antitrypsin. FEBS Lett 1984;169:84-8.
96. McCracken AA, Kruse KB, Brown JL. Molecular basis for defective secretion of variants having altered potential for salt bridge formation between amino acids 240 and 242. Mol Cell Biol 1989;9:1408-14.
97. Sifers RN, Hardick CP, Woo SLC. Disruption of the 240-342 salt bridge is not responsible for the defect of the PIZ α1-antitrypsin variant. J Biol Chem1989;264:2997-3001.
98. Wu Y, Foreman RC. The effect of amino acid substitutions at position 342 on the secretion of human α1-antitrypsin from Xenopus oocytes. FEBS Lett 1990;268:21-3.
99. Lomas DA, Evans DL, Finch JJ, et al. The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 1992;357:605-7.
100. Yamasaki M, Li W, Johnson DJD, Huntington JA. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 2008;455:1255-8.
101. Lomas DA, Finch JT, Seyama K, et al. α1-Antitrypsin Siiyama (Ser53 Phe): further evidence for intracellular loop-sheet polymerization. J Biol Chem 1993;268:15333-5.
102. Lomas DA, Elliott PR, Sidhar SK, et al. α1-Antitrypsin MMalton (Phe52 deleted) forms loop-sheet polymers in vivo: evidence for the C-sheet mechanism of polymerization. J Biol Chem 1995;270:16864-74.
103. Elliott PR, Stein PE, Bilton D, et al. Structural explanation for the deficiency of S α1-antitrypsin. Nat Struct Biol 1996;3:910-11.
104. Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins wibble and wobble (T85M/K): archetypal conformational disease with in vivo latent-transition, thrombosis and heparin activation. Blood 1998;92:2696-706.
105. Eldering E, Verpy E, Roem D, et al. Carboxyl-terminal substitutions in the serpin C1 inhibitor that cause loop over insertion and subsequent multimerization. J Biol Chem1995;270:2579-87.
106. Davis RL, Shrimpton AE, Holohan PD, et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999;401:376-9.
107. Kim J, Lee KN, Yi GS, et al. A thermostable mutation located at the hydrophobic core of α1-antitrypsin suppresses the folding defect of the Z-type variant. J Biol Chem1995;270:8597-601.
108. Sidhar SK, Lomas DA, Carrell RW, et al. Mutations which impede loop-sheet polymerization enhance the secretion of human α1-antitrypsin deficiency variants. J Biol Chem1995;270:8393-6.
109. Kang HA, Lee KN, Yu MH. Folding and stability of the Z and Siiyama genetic variants of human α1-antitrypsin. J Biol Chem 1997;272:510-16.
110. Schmidt B, Perlmutter DH. GRP78, GRP94 and GRP170 interact with α1 AT mutants that are retained in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol 2005;289:G444-55.
111. Brodsky JL, Wojcikiewicz RJ. Substrate-specific mediators of ERassociated degradation. Curr Opin Cell Biol 2009;21:516-21.
112. Maattanen P, Gehring K, Bergeron JJM, Thomas DY. Protein quality control in the ER: the recognition of misfolded proteins. Semin Cell Develop Biol 2010;21:500-11.
113. Nyfeler B, Reiterer V, Wendeler MW, et al. Identification of ERGIC-53 as an intracellular transport receptor of α1-antitrypsin. J Cell Biol 2008;180:705-12.
114. Dycaico JM, Grant SGN, Felts K, et al. Neonatal hepatitis induced by α1-antitrypsin: a transgenic mouse model. Science 1988;242:1404-12.
115. Carlson JA, Rogers BB, Sifers RN, et al. Accumulation of PIZ antitrypsin causes liver damage in transgenic mice. J Clin Invest 1988;83:1183-90.
116. Perlmutter DH. Liver injury in α1 AT deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest 2002;110:233-8.
117. Wu Y, Whitman I, Molmenti E, et al. A lag in intracellular degradation of mutant α1-antitrypsin correlates with the liver disease phenotype in homozygous PIZZ α1-antitrypsin deficiency. Proc Natl Acad Sci USA 1994;91:9014-18.
118. Werner ED, Brodsky JL, McCracken AA. Proteasome-dependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate. Proc Natl Acad Sci USA 1996;93:13797-801.
119. Qu D, Teckman TH, Omura S, et al. Degradation of mutant secretory protein, α1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem1996;271:22791-5.
120. Teckman JH, Gilmore R, Perlmutter DH. The role of ubiquitin in proteasomal degradation of mutant α1-antitrypsin Z in the endoplasmic reticulum. Am J Physiol 2000;278:G38-48.
121. Teckman JH, Burrows J, Hidvegi T, et al. The proteasome participants in degradation of mutant α1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes. J Biol Chem 2001;276:44865-72.
122. Mayer T, Braun T, Jentsch S. Role of the proteasome in membrane extraction of a short-lived ER-transmembrane protein. EMBO J 1998;17:3251-7.
123. Teckman JH, Perlmutter DH. Retention of the mutant secretory protein-1-antitrypsin Z in the endoplasmic reticulum induces autophagy. Am J Physiol 2000;279:G961-74.
124. Kamimoto T, Shoji S, Mizushima N, et al. The intracellular inclusions containing mutant-1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem2006;281:4467-76.
125. Kruse KB, Brodsky JL, McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble A1PiZ and another for aggregates of A1PiZ. Mol Biol Cell 2006;17:203-12.
126. Kruse K, Dear A, Kaltenbrun ER, et al. Mutant fibrinogen cleared from the endoplasmic reticulum via endoplasmic reticulumassociated protein degradation and autophagy: an explanation for liver disease. Am J Pathol 2006;168:1300-8.
127. Cabral CM, Liu Y, Moremen KW, Sifers RN. Organizational diversity among distinct glycoprotein endoplasmic reticulum-associated degradation programs. Mol Cell Biol 2002;13:2639-50.
128. Pan S, Huang L, McPherson J, et al. Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha-1-antitrypsin deficiency. Hepatology 2009;50:275-81.
129. Chappell S, Hadzic N, Stockley R, Guetta-Baranes T, Morgan K, Kalsheker N. A polymorphism of the alpha-1-antitrypsin gene represents a risk factor for liver disease. Hepatology 2008;47:127-32.
130. Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH. Accumulation of mutant α1-antitrypsin Z in the ER activates caspases-4 and -12, NF_B and BAP31 but not the unfolded protein response. J Biol Chem 2005;280:39002-15.
131. Hidvegi T, Mirnics K, Hale P, Ewing M, Beckett C, Perlmutter DH. Regulator of G signaling 16 is a marker for the distinct endoplasmic reticulum stress state associated with aggregated mutant α1-antitrypsin Z in the classical form of α1-antitrypsin deficiency. J Biol Chem 2007;282:27769-80.
132. Liao Y, Shikapwashya ON, Shteyer E, Dieckgraefe BK, Hruz PW, Rudnick DA. Delayed hepatocellular mitotic progression and impaired liver regeneration in early growth response-1-deficient mice. J Biol Chem2004;279:43107-16.
133. Gohla A, Klement K, Piekorz RP, et al. An obligatory requirement for the heterotrimeric G protein G_i3 in the antiautophagic action of insulin in the liver. Proc Natl Acad Sci USA 2007;104:3003-8.
134. Geller SA, Nichols WS, Dycaico MJ, et al. Histopathology of α1-antitrypsin liver disease in a transgenic mouse model. Hepatology 1990;12:40-7.
135. Geller SA, Nichols WS, Kim SS, et al. Hepatocarcinogenesis is the sequel to hepatitis in Z#2 α1-antitrypsin transgenic mice: histopathological and DNA ploidy studies. Hepatology 1994;19:389-97.
136. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995;22:1317-25.
137. Teckman JH, An JK, Blomenkamp K, et al. Mitochondrial autophagy and injury in the liver in α1-antitrypsin deficiency. Am J Physiol 2004;286:G851-62.
138. Rudnick DA, Liao Y, An JK, et al. Analyses of hepatocellular proliferation in a mouse model of α1-antitrypsin deficiency. Hepatology 2004;39:1048-55.
139. Linblad D, Blomenkamp K, Teckman J. Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatology 2007;46:1228-35.
140. Rudnick DA, Perlmutter DH. Alpha-1-Antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005;42:514-21.
141. An JK, Blomenkamp K, Lindblad D, Teckman JH. Quantitative isolation of alpha1AT mutant Z polymers from human and mouse livers and the effect of heat. Hepatology 2005;41:160-7.
142. Steiner SJ, Gupta SK, Croffie JM, et al. Serumlevels of α1-antitrypsin predict phenotypic expression of the α1-antitrypsin gene. DigDis Sci 2003;48:1793-6.
143. Qizibash A, Yong-Pong O. Alpha-1-antitrypsin liver disease: differential diagnosis of PAS-positive diastase-resistant globules in liver cells. Am J Clin Pathol 1983;79:697-702.
144. Yunis EJ, Agostini RM, Glew RH. Fine structural observations of the liver in α1-antitrypsin deficiency. Am J Clin Pathol 1976;82:265-86.
145. Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008;40:1492-4.
146. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009;78:959-91.
147. Burrows JAJ, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency. Proc Natl Acad Sci USA 2000;97:1796-801.
148. Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Ped Gastroenterol Nutr 2004;39:34-7.
149. Boelens J, Lust S, Offner F, Bracke ME, Vanhoecke BW. The endoplasmic reticulum: a taget for new anticancer drugs [Review]. In Vivo 2007;21:215-26.
150. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2007;140:900-17.
151. Renna M, Jimenez-Sanchez M, Sarkar S, Rubinsztein DC. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem 2010;285: 11061-7.
152. Zhang L, Yu J, Pan H, et al. Small molecule regulators of autophagy identified by image-based high-throughput screen. Proc Natl Acad Sci USA 2007;104:19023-8.
153. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin. Am J Respir Crit Care Med 1998;158:49-59.
154. Campbell EF, Campbell MA, Boukedes SS, et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in α1-antitrypsin deficiency. J Clin Invest 1999;104:337-44.
155. Cassivi SD, Meyers BF, Battafarano RJ, et al.. Thirteeen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002;74:1663-9.
156. Wang L, Wang H, Bell P, et al. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther 2010;18:118-25.
157. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007;117:3633-41.
158. Rhim JA, Sandgen EP, Degen JL, et al. Replacement of disease mouse liver by hepatic cell transplantation. Science 1994;263: 1149-52.
159. Overturf K, Al-Dhalimy M, Tanguay R, et al. Hepatocytes corrected by gene therapy are selected in vivo in amurinemodel of hereditary tyrosinaemia type I. Nat Genet 1996;12:266-73.
160. Paulk NK, Wursthorn K, Wand Z, Finegold MJ, Kay MA, Grompe M. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 2010;51:1200-8.
161. Kidd VJ, Golbus MS, Wallace RB, et al. Prenatal diagnosis of α1-antitrypsin deficiency by direct analysis of the mutation site in the genes. N Engl J Med 1984;310:639-42.
162. Psacharopoulos HT, Mowat AP, Cook PJL, et al. Outcome of liver disease associated with α1-antitrypsin deficiency (PIMZ): implications for genetic counselling and antenatal diagnosis. Arch Dis Child 1983;58:882-7.
163. Sveger T, Thelin T, McNeil TF. Young adults with α1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr 1997;86:37-40.
164. Perlmutter DH. Alpha-1-antitrypsin deficiency. In: Snape WJ, ed. Consultations in Gastroenterology. Philadelphia: WB Saunders; 1996:793.